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Bidirectional signalling between the gastrointestinal tract and the brain is regulated at
neural, hormonal, and immunological levels. This construct is known as the brain–gut axis
and is vital for maintaining homeostasis. Bacterial colonization of the intestine plays a major
role in the post-natal development and maturation of the immune and endocrine systems.
These processes are key factors underpinning central nervous system (CNS) signaling.
Recent research advances have seen a tremendous improvement in our understanding
of the scale, diversity, and importance of the gut microbiome. This has been reﬂected in
the form of a revised nomenclature to the more inclusive brain–gut–enteric microbiota
axis and a sustained research effort to establish how communication along this axis con-
tributes to both normal and pathological conditions. In this review, we will brieﬂy discuss
the critical components of this axis and the methodological challenges that have been pre-
sented in attempts to deﬁne what constitutes a normal microbiota and chart its temporal
development. Emphasis is placed on the new research narrative that conﬁrms the critical
inﬂuence of the microbiota on mood and behavior. Mechanistic insights are provided with
examples of both neural and humoral routes through which these effects can be mediated.
The evidence supporting a role for the enteric ﬂora in brain–gut axis disorders is explored
with the spotlight on the clinical relevance for irritable bowel syndrome, a stress-related
functional gastrointestinal disorder. We also critically evaluate the therapeutic opportuni-
ties arising from this research and consider in particular whether targeting the microbiome
might represent a valid strategy for the management of CNS disorders and ponder the
pitfalls inherent in such an approach. Despite the considerable challenges that lie ahead,
this is an exciting area of research and one that is destined to remain the center of focus
for some time to come.
Keywords: microbiota, central nervous system, enteric nervous system, irritable bowel syndrome, vagus nerve,
inflammation, probiotic, dysbiosis
INTRODUCTION
Scientiﬁc endeavor is increasingly characterized by a multidis-
ciplinary approach to the study of both health and disease.
Nowhere is this more evident than in the ﬁeld of neurogas-
troenterology where the converging inﬂuence of experts across
the diverse domains of gastroenterology, psychiatry, microbiol-
ogy, pharmacology, immunology, and behavioral neuroscience, to
name but a few, have helped shape emerging biological themes.
Chief among these is the concept of the brain–gut axis, a term
which describes the complex bidirectional communication sys-
tem that exists between the central nervous system (CNS) and
the gastrointestinal tract (GIT) and which is vital for maintain-
ing homeostasis (Cryan and O’Mahony, 2011). Spurred in part
by the discovery of Helicobacter pylori as a causative agent in
ulcer diseases but also by other innovative research in the gas-
trointestinal sciences (Pandol, 2010; Shanahan, 2010b), there is a
growing appreciation of the critical role played by the commensal
microbiota, both in our general wellbeing and in the speciﬁc func-
tioning of the brain–gut axis. This has been reﬂected in the form
of a revised nomenclature to the more inclusive brain–gut–enteric
microbiota axis and a sustained research effort to establish how
communication along this axis contributes to both normal and
pathological conditions (Rhee et al., 2009).
In this review, we will brieﬂy discuss the critical compo-
nents of this axis and the methodological challenges that have
been presented in attempts to deﬁne what constitutes a normal
microbiota and chart its temporal development. We examine the
approaches that have been taken to elucidate the impact of the
enteric microﬂora on this axis and vice-versa, with reference to
the previously elucidated functions of the microbiota as well as an
evaluation of exciting newdata suggesting a role for themicrobiota
in the modulation of mood and behavior. Mechanistic insights
are provided and the evidence supporting a role for the micro-
biota in disease states is discussed. The clinical implications are
critically evaluated, therapeutic opportunities arising from these
ﬁndings discussed and future perspectives are provided on this
rapidly expanding area of research.
THE BRAIN–GUT–ENTERIC MICROBIOTA AXIS
The general scaffolding of the brain–gut–enteric microbiota axis
includes the CNS, the neuroendocrine and neuroimmune sys-
tems, the sympathetic andparasympathetic arms of the autonomic
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nervous system (ANS), the enteric nervous system (ENS), and of
course the intestinal microbiota. These components interact to
form a complex reﬂex network with afferent ﬁbers that project to
integrative CNS structures and efferent projections to the smooth
muscle (O’Mahony et al., 2011). Put simply, through this bidi-
rectional communication network, signals from the brain can
inﬂuence the motor, sensory, and secretory modalities of the GIT
and conversely, visceral messages from the GIT can inﬂuence brain
function (O’Mahony et al., 2011). This top-down and bottom-up
perspective of information ﬂow as well as the detailed structural
integration and functioning of the various axis components has
been reviewed extensively elsewhere (Mayer, 2011). Less well stud-
ied but increasingly appreciated is the potential impact of the
enteric microbiota on the alliances within the construct (Rhee
et al., 2009; Cryan and O’Mahony, 2011).
MICROBIOTA COMPOSITION AND DEVELOPMENT
If size matters, then the numerical assessment of the microbiota
ensure that it won’t be found wanting. The GIT is inhabited with
1013–1014 microorganisms, a ﬁgure thought to be 10 times that
of the number of human cells in our bodies and 150 times as
many genes as our genome (Gill et al., 2006; Qin et al., 2010).
The estimated species number varies greatly but it is generally
accepted that the adult microbiome consists of greater than 1000
species (Qin et al., 2010) and more than 7000 strains (Ley et al.,
2006a). It is an environment dominated by bacteria, mainly strict
anaerobes, but also including viruses, protozoa, archae, and fungi
(Gill et al., 2006; Xu et al., 2007). The microbiome is largely
deﬁned by two bacterial phylotypes, Bacteroidetes and Firmicutes
with Proteobacteria, Actinobacteria, Fusobacteria, and Verrucomi-
crobia phyla present in relatively low abundance (Eckburg et al.,
2005).
The surety with which these quantitative and qualitative
descriptions have been advanced belies the methodological dif-
ﬁculty encountered while trying to delineate and enumerate the
constituents of a normal microbiota. Culture based analyses,
the mainstay of traditional microbiological attempts to deﬁne
the enteric ﬂora, are only adequate for the minority of the gut
microbiota that is amenable to cultivation (Eckburg et al., 2005;
Shanahan, 2010a). This problem has largely been circumvented
by the use of culture-independent techniques, a portfolio consist-
ing of sequencing based methods, genetic ﬁngerprinting, ﬂuores-
cently labeled oligonucleotide probes (FISH), quantitative PCR
as well as metagenomic approaches (Sekirov et al., 2010; Archie
and Theis, 2011). The realization that the secretory and meta-
bolic capability of the microbiome was likely as important as
phylotype composition has also led to the use of metabolomic
and metaproteomic approaches to improve our understanding
of what has been described as the forgotten organ (O’Hara and
Shanahan, 2006). Unfortunately, advances in culture methods
have not kept pace with the rise of these alternative technologies
and a dual-pronged line of attack may be required to complete
the circle, a not inconsiderable logistical challenge (Clarke et al.,
2009b). Moreover deﬁcits remain to be redressed in relation to the
microbial content of the small intestine due to an over-reliance
on the analysis of fecal microbial composition (Forsythe et al.,
2010).
As our knowledge of the previously unimagined scale of
microbial diversity within the gut has expanded, so too has an
understanding of its development and longitudinal variation.
Colonization of the infant gut commences at birth when deliv-
ery exposes the infant to a complex microﬂora and its initial
microbiome has a maternal signature (see Figure 1; Mändar
and Mikelsaar, 1996; Mackie et al., 1999; Palmer et al., 2007).
The microbiome of unweaned infants is simple with high inter-
individual variability (McCracken and Lorenz, 2001; Kurokawa
et al., 2007; Adlerberth and Wold, 2009). The numbers and diver-
sity of strict anaerobes increase as a result of diet and environment,
and after 1 year of age a complex adult-like microbiome is evident
(Mackie et al., 1999; Kurokawa et al., 2007; Palmer et al., 2007).
Of note is that a western diet is thought to be culpable for the
development of a microbiota with a tendency toward an enhanced
proinﬂammatory motif (Greer and O’Keefe, 2011; Wu and Hui,
2011). Despite a signiﬁcant interpersonal variation in the enteric
microbiota, there seems to be a balance that confers health beneﬁts
and an alteration in beneﬁcial bacteria can negatively inﬂuence the
wellbeing of the individual (Cryan and O’Mahony, 2011). Several
factors may alter the microbiome such as infection, disease, diet,
and antibiotics, but it tends to revert to the stable diversity estab-
lished in infancy once the threat of the initial distorting factor has
subsided (Forsythe et al., 2010). Interestingly, it has been demon-
strated that the core microbiota of an aged individual is distinct
from that of younger adults (Claesson et al., 2011) and that age
related shifts in the composition of the intestinal microbiota are
linked to adverse health effects in the elderly host (Woodmansey,
2007).
FIGURE 1 | Development of the microbiome in early life. Subsequent to
the sterile uterine environment, colonization begins at birth with facultative
bacteria (blue) colonizing the GIT immediately. The anaerobic bacteria
colonize later (orange). By 1 year of age the microbiome has a stable
adult-like signature. Rodents follow a similar colonization pattern to humans
and this forms the rationale for the use of germ free animals to study the
impact of the microbiota.
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EVALUATING THE ROLE OF THE MICROBIOTA
Of the varied strategies employed to study the function of the
microbiota, perhaps the use of germ-free (GF) animals has offered
the most revealing insights. Their use is based on the sterile
uterine environment present during prenatal development (Adler-
berth and Wold, 2009) with surgical delivery replacing the normal
birthing process, thus eliminating the opportunity for post-natal
colonization of the GIT (see Figure 1). Subsequent comparison
with their conventionally colonized counterparts allows infer-
ences to be drawn regarding the morphological and physiological
parameters that may be under the inﬂuence of the developing
microbiota. However useful the complete absence of an intestinal
microbiota may be in proof of principle studies, it is not reﬂective
of real life scenarios.Other approacheswhich havemore validity in
this regard involve inducement of a dysbiosis of the enteric ﬂora,
either through administration of antibiotics or deliberate infec-
tion in preclinical studies (Cryan and O’Mahony, 2011). Broad
spectrumantibiotics in particular are known to perturb themicro-
biome by reducing biodiversity and delaying colonization and are
widely used as a method to intentionally alter the microbiome in
a reproducible manner (Bennet et al., 2002; Donskey et al., 2003).
The use of cell lines,molecular approaches, and isografts have also
proved useful in evaluating the role of the microbiota (McCracken
and Lorenz, 2001).
FUNCTIONAL RELEVANCE OF THE MICROBIOTA
GF studies have been pivotal in establishing the structural, protec-
tive, and metabolic repertoire of functions that had been assigned
to the microbiota even prior to the resurgence in interest in recent
years (O’Hara and Shanahan, 2006). The morphological conse-
quences of growing up germ-free were evidenced by the greatly
enlarged cecum, reduced intestinal surface area, increased ente-
rochromafﬁn cell area, smaller Peyer’s Patches and smaller villous
thickness in these animals compared to conventional controls
(Wostmann and Bruckner-Kardoss, 1959; Gordon and Bruckner-
Kardoss,1961;Abrams et al., 1963; Shanahan,2002). Itwas perhaps
unsurprising, given these gross structural aberrations, that mul-
tiple facets of normal GIT function would also be affected (see
Figure 2).
Thus it is known that the microbiota is essential for normal
GIT motility, with deﬁcits due in part to perturbations in peristal-
sis on the back of impaired smooth muscle layer function (Berg,
FIGURE 2 | Function of the intestinal microbiome. Commensal bacteria
exert a miscellany of protective, structural, and metabolic effects on the
intestinal mucosa.
1996; Stappenbeck et al., 2002). It is also clear from early stud-
ies that the microbiome is involved in maintenance of barrier
function. Intestinal epithelial cell turnover is much slower in GF
animals than conventionally reared animals (Abrams et al., 1963).
More recent studies substantiate these assertions with demon-
strations that commensal ﬂora recognition by toll-like receptors
(TLRs) is necessary to induce increased epithelial cell prolifer-
ation thus accelerating repair of the epithelial surface following
injury (Rakoff-Nahoum et al., 2004). Monoassociation of GF ani-
mals with Bacteroides thetaiotaomicron, a representative strain of
bacteria from the dominant microbial phyla, up-regulates sprr2a,
a gene involved in desmosome maintenance and reinforcement of
the intestinal barrier (Hooper et al., 2001). Furthermore, activa-
tion of the TLR2 signaling pathway directly enhances intestinal
epithelial integrity through translocation of the tight junction
protein zonula occludens-1 (ZO-1; Cario et al., 2004). Paneth
cells are secretory cells found in small clusters at the base of
crypts of Lieberkühn in the epithelium of the small intestine
and maintain intestinal homeostasis by directly sensing enteric
bacteria at TLRs which trigger the expression of multiple anti-
microbial factors thus controlling intestinal barrier penetration
by commensal and pathogenic bacteria (Vaishnava et al., 2008).
They are known to express and release a wide variety of anti-
microbial peptides including α-defensins and lysozyme C. but
require a complete microbiome to realize a full complement of
these peptides (Hooper et al., 2003; Cash et al., 2006; Vaishnava
et al., 2008).
GF studies also revealed that the microbiota is essential for the
development of the gut associated lymphoid tissue (GALT) and
indeed plays a vital part in shaping the immunological repertoire
of the GIT with IgA secretion and controlled inﬂammation being
regarded a consequence of bacterial colonization (Mayer, 2003;
Quigley, 2008). In comparison to conventionally housed animals,
GF animals have decreased plasma cells and IgA, decreased expres-
sion of activation markers on intestinal macrophages, decreased
MHCII on epithelial cells, decreased nitric oxide, and histamine
levels in the small intestine (Gordon, 1959; Beaver and Wost-
mann, 1962; Glaister, 1973; Moreau et al., 1978; Matsumoto
et al., 1992; Mikkelsen et al., 2004; Sobko et al., 2004; Smith
et al., 2007). Peyer’s patch follicles are reduced in number and
size and the mesenteric lymph nodes are smaller, less cellu-
lar, and do not have germinal centers in GF animals (Gordon,
1959; Glaister, 1973). However, reconstitution of GF mice with an
intestinal microﬂora is sufﬁcient to restore the mucosal immune
system (Umesaki et al., 1995). Moreover, ligands from commen-
sal bacteria such as polysaccharide A, lipopolysaccharide (LPS),
and lipoteichoic acid (LTA) inﬂuence the normal development
and function of the mucosal immune system (Rakoff-Nahoum
et al., 2004; Mazmanian et al., 2005). The basic mechanism of
the mucosal immune system is innate immunity and its char-
acteristic ability to distinguish potentially pathogenic microbes
from harmless antigens is achieved through pattern recognition
receptors (PRR). TLRs are present on cells of the innate immune
system and recognize characteristic molecules called pathogen
associated molecular patterns (PAMPS; Akira and Hemmi, 2003).
Pathogen recognition by a particular TLR results in a cascade of
events starting with the activation of the NF-κB signaling system
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and resulting in increased cytokine production and T cell acti-
vation (Ulevitch, 1999). However in the absence of the resident
enteric ﬂora, key members of the TLR family have low or absent
expression proﬁles in the GIT, thus compromising appropriate
immune responses to pathogenic threats (O’Hara and Shanahan,
2006).
The microbiota also has a critical role in supporting normal
digestion and host metabolism. There are two main mechanisms
by which it can maximize nutrient availability, either by the release
of calories fromotherwise unavailable oligosaccharides or bymod-
ulating absorption (Sekirov et al., 2010). A signiﬁcant energy
source for humans is the bacterial metabolism of dietary ﬁber to
short-chain fatty acids (SCFAs;Macfarlane andMacfarlane, 2003).
SCFAs can modulate the host energy balance through Gpr41, a G
protein coupled receptor that binds SCFA, and is dependent upon
the gut microbiome (Samuel et al., 2008). It is thought that inter-
action between SCFAs produced by the gut bacteria, and Gpr41
increases circulating levels of PYY, an enteroendocrine hormone
that reduces gut motility and thus increases absorption of SCFAs
(Samuel et al., 2008). GF animals require a higher caloric intake
to maintain the same body weight as conventional animals and
are prone to vitamin deﬁciencies, requiring dietary supplementa-
tion with vitamins K and B (Sumi et al., 1977; Wostmann, 1981;
Wostmann et al., 1983).
Prevention of colonization by pathogens is achieved in large
part through the resident microbiota by competing for nutri-
ents and receptors and production of anti-microbial compounds
(Sekirov et al., 2010). Lactobacillus and Biﬁdobacterium are gram
positive bacteria and form two important genera in the micro-
biome. These bacteria were shown to inhibit listerial infections
in vitro. It is thought that Lactobacilli inhibited infection through
a combination of acid production and secretion of an uniden-
tiﬁed protein while Biﬁdobacterium inhibition was attributed to
an extracellular proteinaceous secreted compound (Corr et al.,
2007a). In another study aLactobacillus salivarius strainwas shown
to produce a bacteriocin in vivo that could signiﬁcantly protect
mice against infection with the pathogen Listeria monocytogenes
(Corr et al., 2007b).
MICROBIOTA AND THE CNS
It is clear then from the gamut of functions under the inﬂuence of
the microbiota – regulation of the mucosal immune system, GIT
motility, and epithelial barrier function, support for digestion/host
metabolism and prevention of colonization by pathogens – that
critical components of the brain–gut axis other than the GIT itself
might also be subject to manipulation by the microbiome. More
speciﬁcally, the potential inﬂuence of the commensal bacteria on
CNS signaling is currently, after a slow start, a burgeoning area of
research.
The core neuroendocrine pathway in man is the hypothalamic–
pituitary–adrenal (HPA) axis and activation of this axis takes place
in response to a variety of physical and psychological stressors
(Dinan et al., 2006). After much initial speculation, an elegant
study by Sudo et al. (2004) provided some insight into the role of
the intestinal microbiota in the development of the HPA axis. In
GF mice a mild restraint stress induced an exaggerated release
of corticosterone and adrenocorticotrophin hormone (ACTH)
compared to the speciﬁc pathogen free (SPF) controls. The stress
response in the GF mice was partially reversed by recolonization
with fecal matter from SPF animals and fully reversed by monoas-
sociation with B. infantis in a time dependant manner (Sudo
et al., 2004). This study clearly demonstrated that the microbial
content of the GIT is critical to the development of an appro-
priate stress response later in life and also that there is a critical
window in early life where colonization must occur to ensure
normal development of the HPA axis. Sudo et al. (2004) also
reported a decrease in brain derived neurotrophic factor (BDNF),
a key neurotrophin involved in neuronal growth and survival,
and expression of the NMDA receptor subunit 2a (NR2a) in
the cortex and hippocampus of GF animals compared to SPF
controls.
The encouraging ﬁndings from this study prompted further
research in this area, especially with a view to establishing a
behavioral phenotype and neurochemical proﬁle that might be
associated with the gut ﬂora. To date, the most consistent data
has been in relation to indices of anxiety. Neufeld et al. (2011),
despite reporting an unexplained increase in BDNF mRNA that
was contrary to the protein decreases observed in the earlier study,
reported a less anxious phenotype for germ free animals in the ele-
vated plus maze (EPM). This behavioral phenotype was replicated
in another study with GF animals in both the EPM and the light
dark box and associated with an altered gene expression proﬁle in
relevant brain regions (Heijtz et al., 2011). Probiotic administra-
tion studies also weigh in on the side of a role for the microbiota
in anxiety-like behaviors with, for example, administration of L.
helveticus R0052 and B. longum R0175 taken in combination dis-
playing anxiolytic-like activity in rats (Messaoudi et al., 2011).
Moreover, a recent study reported that chronic treatment with
the probiotic L. rhamnosus (JB-1) over 28 days produced animals
with lower levels of stress-induced corticosterone and reduced
depressive behaviors in the forced swim test in addition to a less
anxious phenotype in the EPM. The L. rhamnosus (JB-1) treated
animals also showed alterations of GABAB1b mRNA in the brain
with increased expression in cortical regions and decreased expres-
sion in the hippocampus, amygdala, and locus coeruleus as well
as reduced GABAAα2 mRNA expression in the prefrontal cortex
and amygdala and increased GABAAα2 in the hippocampus. Inter-
estingly the authors demonstrated that vagotomized mice did not
display the neurochemical and behavioral effects of this bacterium,
thus implicating the vagus nerve in the direct communication
between the bacteria and the brain (Bravo et al., 2011). A role
for the gut microbiota in pain perception has also been proposed
(Forsythe et al., 2010),with, for example, one study demonstrating
that speciﬁc Lactobacillus strains could induce the expression of μ-
opioid and cannabinoid receptors in intestinal epithelial cells and
mimic the effects of morphine in promoting analgesia (Rousseaux
et al., 2007).
A strategy employing antibiotic-induced dysbiosis of the
microbiome, in this case a cocktail consisting of neomycin, baci-
tracin, and the antifungal agent pimaricin, resulted in mice which
displayed less anxiety-like behaviors in the both the step down
box and the light/dark box test. Interestingly the authors also
reported altered protein levels of BDNF in the amygdala and
hippocampus and that discontinuation of the antibiotic cocktail
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restored the normal behavioral proﬁle of the animals (Bercik et al.,
2011). Similarly perturbation of the microbiota by means of an
infectious agent like Citrobacter rodentium has been shown to
increase anxiety-like behavior in mice 7–8 h post infection as
measured in the hole board open ﬁeld apparatus (Lyte et al.,
2006) and to produce stress-induced memory dysfunction 10 and
30 days post infection (Gareau et al., 2011). Moreover, memory
dysfunction was prevented by daily administration of a probi-
otic cocktail and when GF mice were infected they developed
memory dysfunction regardless of whether they were stressed
or not.
INFLUENCE OF THE BRAIN ON THE MICROBIOME
Although the bulk of research to date has focused on the impact
of the microbiota on CNS function, there is also research to sug-
gest that the brain can alter the microbiome. Signaling molecules
released into the gut lumen from cells in the lamina propria
that are under the control of the CNS can result in changes in
gastrointestinal motility and secretion as well as intestinal perme-
ability, thus altering the GIT environment in which the bacteria
reside (Rhee et al., 2009). Stress also induces permeability of the
gut allowing bacteria and bacterial antigens to cross the epithe-
lial barrier and this can activate a mucosal immune response
which in turn alters the composition of the microbiome (Kili-
aan et al., 1998). Acute stress was shown to cause an increase
in colonic paracellular permeability which involved mast cells
and overproduction of IFN-γ with decreased expression of ZO-2
and occludin mRNA (Demaude et al., 2006). The psychological
components of social stress was shown to facilitate the translo-
cation of indigenous bacteria into the host (Bailey et al., 2006).
Other studies have shown that stress hormones promoted the
growth of non-pathogenic isolates of Escherichia coli as well as
the pathogenic E. coli 0157:H7 strain via interactions with host
catecholamines such as adrenaline and noradrenaline (Freestone
et al., 2002, 2003). Different psychological stressors are known
to alter the composition of the microbiome by modulating the
composition of total biomass in infants (Rhee et al., 2009). Pre-
natal stressors have been shown to alter the microbiome in rhesus
monkeys by reducing the overall numbers of Biﬁdobacteria and
Lactobacilli (Bailey et al., 2004). Maternal separation, an early
life stressor, caused a signiﬁcant decrease in fecal Lactobacilli on
day 3 post separation, which returned to baseline by day 7 as
assessed by enumeration of total and gram-negative aerobic and
facultative anaerobic bacterial species (Bailey and Coe, 1999).
However, early life stress can also have long term effects on the
microbiome. Analysis of the 16S rRNA diversity in adult rats
exposed to maternal separation for 3 h per day from post-natal
days 2–12 revealed a signiﬁcantly altered fecal microbiome when
compared to the non-separated control animals (O’Mahony et al.,
2009).
MECHANISMS OF ACTION
A number of mechanisms have been proposed through which the
intestinal communal microﬂora might inﬂuence ENS and CNS
signaling, including both neural and humoral routes as well as
direct and indirect modes of action (see Figure 3; Forsythe et al.,
2010). Perhaps the best evidence to date comes from a novel recent
FIGURE 3 | Proposed mechanisms of action.There are a variety of
proposed mechanisms, including both humoral and neural routes, through
which the microbiota can modulate signaling along the brain–gut axis. For
example, recent studies suggest a role for both the vagus nerve and
modulation of systemic tryptophan levels in relaying the inﬂuence of both
resident and exogenous microﬂora along this bidirectional communication
axis.
study which conclusively implicated the vagus nerve in the direct
communication observed between the bacteria and the brain (see
earlier sections for detailed description; Bravo et al., 2011). Fur-
ther studies are required to clarify the precise route though which
the administered probiotic interacts with the vagus nerve but in
any case this study conﬁrmed a mechanism many had previously
suggested as a likely contender (Cryan and O’Mahony, 2011).
Other potential mechanisms of action include neurotransmitter
modulation. B. infantis 35624, for example, has been shown to
induce an elevation in plasma tryptophan levels, a precursor to
serotonin (5-HT) which is a key neurotransmitter within the
brain–gut axis, in Sprague-Dawley rats (Desbonnet et al., 2008).
Since CNS tryptophan concentrations are largely dependant on
peripheral availability and the enzymatic machinery responsible
for the production of 5-HT is not saturated at normal tryptophan
concentrations (Ruddick et al., 2006), the implication here is that
the microbiota might play some role in the regulation of CNS as
well as ENS 5-HT synthesis. This effect is potentially mediated
by the effect of the microbiota on the expression of indoleamine-
2,3-dioxygenase, a key enzyme in the physiologically dominant
kynurenine pathway of tryptophan degradation (Forsythe et al.,
2010). Of course multiple mechanisms are possible and indeed
likely, given the strain speciﬁc effects that have been observed in
many probiotic studies to date (Quigley, 2008).
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MICROBIOTA IN DISEASE
Since the microbiota is involved in maintaining homeostasis and
wellbeing, the proposition that it may also be involved both in gas-
trointestinal and systemic illnesses is a logical one (see Figure 4).
As might be expected given the importance of the microbiota in
supporting host digestion and metabolism, obesity has been con-
sidered as an illness with a potential microbial basis. It has been
deﬁned as a medical condition in which excess body fat has accu-
mulated to produce adverse effects on health, leading to increased
health problems and potentially a reduced life expectancy (Haslam
and James, 2005). The incidence of obesity is increasing in both
developed and developing countries and has become a worldwide
burden upon health care systems (Bloom et al., 2008). Some of
the most convincing evidence comes from studies in GF ani-
mals which have shown them to be naturally leaner than their
SPF counterparts and colonization of adult GF mice with a nor-
mal microbiota from the cecum of conventionally raised animals
produces a 60% increase in body fat content and insulin resis-
tance within 14 days despite reduced food intake (Bäckhed et al.,
2004). GF mice are resistant to diet induced obesity but when col-
onized with fecal ﬂora from SPF mice they gained weight due
to altered fatty acid metabolism (Bäckhed et al., 2007). Other
studies have shown that the ob/ob mouse, a strain of mouse
genetically predisposed to obesity, had a 50% decrease in the
abundance of Bacteroidetes and a proportional increase in Fir-
micutes when compared to the lean wild type and heterozygotic
FIGURE 4 | Brain–gut–microbe communication in health and disease. A
stable gut microbiota is essential for normal gut physiology and contributes
to appropriate signaling along the brain–gut axis and to the healthy status of
the individual as shown on the left hand side of the diagram. Conversely, as
shown on the right hand side of the diagram, intestinal dysbiosis can
adversely inﬂuence gut physiology leading to inappropriate brain–gut axis
signaling and associated consequences for CNS functions and disease
states. Stress at the level of the CNS can also impact on gut function and
lead to perturbations of the microbiota.
controls (Ley et al., 2005). In humans, when the fecal microbiota
of obese individuals was compared to lean controls there were
fewer Bacteroides and more Firmicutes in the obese group. How-
ever, over time on a calorie restricted diet the relative abundance of
Bacteroidetes increased and the abundance of Firmicutes decreased
(Ley et al., 2006b). While these studies do offer some support
for a purturbations of the resident ﬂora in the accumulation
of excess fat, microbial inﬂuences should not be considered in
isolation: obesity is a multifactorial condition that also involves
strong genetic factors, hypothalamic dysfunction, and an increase
in the consumption of energy-dense food (Schellekens et al.,
2010).
Less intuitive is a potential role for the microbiota in the devel-
opment of autism, a developmental disorder that appears in the
ﬁrst 3 years of life and affects the brain’s normal development of
social and communication skills (American Psychiatric Associa-
tion, 2000). Interestingly in a study of 58 autism patients >90%
had gastrointestinal problems compared to none in the control
group (Parracho et al., 2005). Although the underlying etiology of
autism is not well understood, late onset autism is hypothesized
to be caused by extensive use of antibiotics with an association
with Trimethoprim/sulfamethoxazole antibiotic treatment (Bolte,
1998; Finegold et al., 2002). There is evidence to support alter-
ations of the fecal microbiota in patients with autism, with an
increase in several subtypes of Clostridium (Song et al., 2004;
Finegold et al., 2010) and in the majority of cases treatment with
vancomycin, an antibiotic that targets grampositive anaerobes and
isminimally absorbed by theGIT, can improve symptoms (Sandler
et al., 2000). It is further hypothesized that Clostridium spores are
responsible for relapse after completion of the antibiotic treatment
and that a treatment targeting these spores alleviates symptoms for
longer periods (Finegold, 2008).
Within the realm of gastrointestinal disorders, inﬂammatory
bowel disease (IBD), which includes the two distinct disease pat-
terns of ulcerative colitis (UC) and Crohn’s disease (CD; Lichten-
stein,2000;Blumberg andStrober,2001;Podolsky,2002;MacDon-
ald and Monteleone, 2005), has attracted attention as a disorder
with an aberrant GIT microbial signature (Shanahan, 2004). Sev-
eral studies have shown altered gut microbiota in patients with
IBD although it is not clear whether these changes are responsible
for causing disease or are the result of inﬂammatory responses and
extensive tissue changes in the GIT (Macfarlane et al., 2009). This
was not clariﬁed by a studywhich showed that themicrobiomewas
also signiﬁcantly altered in mucosal biopsies taken from inﬂamed
compared to healthy sites (Walker et al., 2011). The changes in the
microbiota are characterized by increases in Proteobacteria and a
decline in Firmicutes and Bacteroidetes (Frank et al., 2007; Walker
et al., 2011). This alteredmicrobiota is also evident in animalmod-
els of inﬂammation relevant to IBD with a dramatic increase in
the Proteobacteria classes of bacteria evident (Lupp et al., 2007).
Interestingly although a Bacteroides species has been shown to col-
onize both genetically IBD susceptible and non-susceptible mice
to the same extent, it only engendered disease in the susceptible
animals (Bloom et al., 2011). Furthermore, in terms of exoge-
nous microbial threats, the frequency of Clostridium difﬁcile has
been shown to be higher in IBD and may trigger relapse where
the disease is established but in remission (Clayton et al., 2009).
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Although the pathogenesis of IBD is still not completely under-
stood, it is well recognized that psychological stress, a factor which
can perturb the microbiota, exacerbates the condition (Mawdsley
and Rampton, 2006; Reber, 2011). However it should be recog-
nized that IBD has a complex and multifaceted etiology, involving
environmental and genetic factors which cause dysregulation of
the mucosal immune system (Andus and Gross, 2000; MacDon-
ald and Monteleone, 2005). Thus, while the microbiota might
not be the sole driving force in IBD, most consider that host–
ﬂora interactions underpin the disorder, especially in genetically
susceptible individuals (Shanahan, 2005; Melgar and Shanahan,
2010).
The best evidence to date for the involvement of the microbiota
in disease states comes from irritable bowel syndrome (IBS), a
prototypical stress-related brain–gut axis disorder. IBS is the most
common functional gastrointestinal disorder (FGID) encountered
in clinical settings (Camilleri, 2001), affecting an estimated 10–
15% of the general population in Western Europe and North
America (Quigley, 2011). It is characterized by the presence of
abdominal pain or discomfort, an alteration in bowel habit, and
the absence of reliable biomarkers (Thompson et al., 1999; Dross-
man et al., 2002; Clarke et al., 2009b). A number of strands of
evidence support a role for the microbiota in the pathophysi-
ology of IBS and chief among these is the supporting data for
post-infectious IBS (PI-IBS), a term which describes the develop-
ment of IBS following an episode of bacteriologically conﬁrmed
gastroenteritis (Quigley, 2009; Sarna, 2011). This phenomenon is
now well documented (Gwee et al., 1999, 2003; Rodríguez and
Ruigómez, 1999; Marshall et al., 2006, 2007) and prospective stud-
ies showing that the risk of developing PI-IBS is in the order of
3–36% following an enteric infection with the precise incidence
depending on the infecting organism (Spiller and Garsed, 2009).
The highest reported incidence of PI-IBS was associated with the
Walkerton outbreak with 36% of individuals showing symptoms
of IBS 2 years after infection with both Campylobacter jejuni and
E. coli 0157:H7 (Marshall et al., 2006). A mechanistic perspective
has been provided by a number of studies which found a persistent
elevation in rectal mucosal enteroendocrine cells, T-lymphocytes
and gut permeability following the infectious insult in subjects
who went on to develop IBS (Spiller et al., 2000; Dunlop et al.,
2003). These studies are regarded as important indicators of a link
between alterations in the microbiota and mucosal inﬂammation
in IBS (Quigley, 2009).
On the basis that immunological changes in IBS might result
from exposure to exogenous bacterial challenge, studies sup-
porting the low grade inﬂammation that has so frequently been
reported in IBS are also taken as evidence of a role for the micro-
bial perturbations in the disorder (Clarke et al., 2009b; Quigley,
2009). Persistent low grade inﬂammation is a characteristic of PI-
IBS (Gwee et al., 1999) and these patients exhibit greater IL-1β
mRNA expression, both during and after the infection, com-
pared with individuals who do not develop PI-IBS (Gwee et al.,
2003). IBS patients with normal histology had increased intraep-
ithelial lymphocytes and CD3+ and CD25+ cells in the lamina
propria (Chadwick et al., 2002). Increased CD25+ cells in IBS
suggests an antigen challenge and these cells are preventing “a
more ﬂorid inﬂammatory response” (Collins, 2002). There are
increased numbers of activated mast cells in colonic biopsies from
IBS patients and a direct correlation between proximity of the
mast cells to neurons and pain severity (Barbara et al., 2004).
Cenac et al. (2007) demonstrated increased proteolytic activity in
colonic washes from IBS compared with control patients while the
analysis of TLR expression in colonic biopsies has demonstrated
increased expression of TLR4 and TLR5 and decreased levels of
TLR7 and TLR8 in IBS patients (Brint et al., 2011).
Others have investigated the involvement of the systemic
immune system on the basis that it might reﬂect mucosal
disturbances. In a study of 78 IBS patients O’Mahony et al.
(2005) demonstrated an abnormal IL-10/IL-12 ratio in stimulated
peripheral blood mononuclear cells (PBMCs), indicating a proin-
ﬂammatory,Th-1 state. Liebregts et al. (2007) showed an enhanced
proinﬂammatory cytokine release (TNF-α, IL-1β, IL-6) in LPS
stimulated PBMCs from IBS patients. In another study, baseline
plasma proinﬂammatory cytokines IL-6, IL-6R, and IL-8 were ele-
vated in IBS and accompanied by overactivation of the HPA axis
(Dinan et al., 2006). Indeed elevations in systemic proinﬂamma-
torymediators have repeatedly beingdemonstrated inboth clinical
datasets and reports from animal models of the disorder (Dinan
et al., 2008; Clarke et al., 2009a, 2010; O’Mahony et al., 2009;
Scully et al., 2010). What is not clear is whether they truly rep-
resent a disturbance at mucosal sites and this remains a subject
in need of further investigation. Interestingly it has recently been
reported that IBS patients have a distinct pattern of exaggerated
peripheral TLR activity as indicated by measurements of cytokine
production following whole blood stimulations (McKernan et al.,
2011).
The qualitative alterations and temporal instability that have
been reported in the enteric ﬂora in IBS cohorts, summarized in
Table 1, is taken as further evidence of an involvement in disease
pathophysiology and is backed up by data from animal models
of the disorder (O’Mahony et al., 2009; Quigley, 2009). While it is
unclear at present is whether these changes in the ﬂora are primary
or secondary and although they have proven difﬁcult to repro-
duce in many cases, there are certainly routes through which they
could impact on symptom pathogenesis (Quigley, 2009). Quanti-
tative alterations in the ﬂora, which have centered around claims
of small intestinal bacterial overgrowth (SIBO) and have in some
cases formed the proposed basis for the efﬁcacy of antibiotics such
as rifaximin in IBS, are more controversial with critics question-
ing both the speciﬁcity and validity of the measurements (Quigley,
2007). This is also contrary to the view that antibiotics might be a
risk factor for the development of IBS (Collins et al., 2009).
THERAPEUTIC OPPORTUNITIES
Although modulation of the microbiota has primarily been a
source of evidence for the functional importance of the commen-
sal load in health, the swell of studies implicating our resident
microﬂora in disease states such as IBS means that this could also
be a strategy with therapeutic potential. There is mounting evi-
dence to support the use of antibiotics, prebiotic substances, and
probiotics with the latter option in particular enjoying some suc-
cess as a treatment option in IBS (Quigley, 2008; Rhee et al., 2009).
Thus, although the effects appear to be strain speciﬁc, cumula-
tive data from the clinical trials to date suggest a role for certain
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Table 1 | Studies which have shown altered fecal and mucosal microbiome in disease states.
Group Method, microbiota analyzed Diagnostic criteria and subjects Finding Reference
IBS Q-PCR, fecal microbiome Rome II, n=27 ↓ Lactobacillus spp. in IBS-D subjects Malinen
et al. (2005)BS-D (n=12), IBS-C (n=9),
IBS-A (n=6)
↑ Veillonella spp. in IBS-C
Culture/DGGE, fecal
microbiome
Rome II, n=26 Increased number of aerobes in IBS patients Mättö et al.
(2005)BS-D (n=12), IBS-C (n=9),
IBS-A (n=5)
Temporal instability in IBS patients revealed by DGGE
Q-PCR, Phylogenic
Microarray, fecal microbiome
Rome II, n=62
IBS-D (n=25), IBS-C (n=18),
IBS-A (n=19)
↑ Ratio of the Firmicutes to Bacteroidetes in IBS Rajilic-
Stojanovic
et al., 2011)
↑ in numbers of Dorea, Ruminococcus, and
Clostridium spp. in IBS
↓ Bacteroidetes in IBS
↓ Biﬁdobacterium and Faecalibacterium spp.
↓ Average number of methanogens in IBS
Fractionation/16S rRNA gene
cloning and sequencing,
Q-PCR, fecal microbiome
Rome II, n=24 Signiﬁcant differences in Coprococcus, Collinsella, and
Coprobacillus Phyla in the IBS group compared to
controls
Kassinen
et al. (2007)IBS-D (n=10), IBS-C (n=8),
IBS-A (n=6)
DGGE, fecal microbiome Rome II, n=47 Signiﬁcant difference between IBS and healthy
controls
Codling
et al. (2010)
No sub-typing Signiﬁcantly more variation in microbiota of healthy
volunteers than that of IBS patients
FISH, fecal and duodenal
microbiome
Rome II, n=41 ↓ Biﬁdobacteria in IBS subjects compared to healthy
controls
Kerckhoffs
et al. (2009)IBS-D (n=14) IBS-C (n=11)
IBS-A (n=16)
Q-PCR, fecal microbiome Rome II and III, n=26 ↑ Veillonella and Lactobacillus in IBS Tana et al.
(2010)IBS-D (n=8) IBS-C (n=11) IBS-A
(n=7)
IBD FISH adapted to ﬂow
cytometry, fecal microbiota
Active CD (n=13) Clostridium coccoides was reduced in UC Sokol et al.
(2006)Active UC (n=13) C. leptum group was reduced in CD
IC (n=5), HS (n=13). Bacteroides group was more abundant in IC
16S rRNA DGGE analysis,
fecal microbiota
Active CD (n=5)
Inactive CD (n=11), HS (n=18)
↓Temporal stability of dominant species for all Crohn’s
disease patients
Scanlan
et al. (2006)
Biﬁdobacterium spp. were similar in all samples
Clostridiales and Bacteroidales communities are
altered in Crohn’s disease
DGGE, Q-PCR, fecal
microbiota
CD (n=68)
Unaffected relatives (n=84), HS
(n=55)
CD vs. unaffected relatives Joossens
et al. (2011)↓ Dialister invisus, an uncharacterized species of
Clostridium cluster XIVa, Faecalibacterium prausnitzii
and Biﬁdobacterium adolescentis
↑ Ruminococcus gnavus
Unaffected relatives vs. HS
↓ Collinsella aerofaciens and member of the
Escherichia coli–Shigella group
↑ Ruminococcus torques
T-RFLP analysis16S rRNA
gene, Q-PCR, ileal and rectal
biopsies
Monozygotic twin pairs that
were discordant (n=6) or
concordant (n=4) for CD, HS
(n=6)
Predominantly ileal CD vs. co-twins and CD localized
in the colon
Willing et al.
(2009)
↓ Faecalibacterium prausnitzii
↑ Escherichia coli
16S rRNA gene sequencing,
mucosal biopsies
Inﬂamed and non-inﬂamed
intestinal tissue from 6 CD
(n=12), 6 UC (n=12), HS (n=5)
↓ Mucosal microbial diversity in IBD Walker et al.
(2011)↓ Firmicutes in IBD samples and ↑ Bacteroidetes
↑ Enterobacteriaceae in CD only signiﬁcant
differences in microbial community structure between
inﬂamed and non-inﬂamed mucosal sites
rRNA sequence analysis and
Q-PCR
UC (n=61), CD (n=68) ↓ Bacteroidetes and Lachnospiraceae in IBD Frank et al.
(2007)HS (n=61) ↑ Actinobacteria and Proteobacteria in IBD
(Continued)
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Table 1 | Continued
Group Method, microbiota analyzed Diagnostic criteria and subjects Finding Reference
Obesity Pyrosequencing, cecal
contents
Ob/Ob mice ↑ Firmicutes Turnbaugh
et al. (2006)↓ Firmicute to Bacteroides ratio
16S rRNA sequencing, cecal
contents
Ob/Ob mice ↓ Bacteroidetes ob/ob animals Ley et al.
(2005)↑ Firmicutes
16S rRNA sequencing Human ↓ Bacteroides in obesity Ley et al.
(2006b)↑ Bacteroides during calorie restriction
Q-PCR, MALDI-TOF spectral
analysis, fecal microbiota
Human Biﬁdobacterium animalis and Methanobrevibacter
smithii were associated with normal bodyweight
Million et al.
(2011)
Lactobacillus reuteri was associated with obesity
Autism Q-PCR, fecal microbiota Autistic (n=15), HS (n=8) ↑ Clostridium bolteae and Clostridium clusters I and
XI in autistic children
Song et al.
(2004)
↓ Clostridium cluster XIVab in autistic children
16S rRNA gene sequencing
and culture, fecal microbiota
Gastric and duodenal
sampling
Autistic (n=13), HS (n=8) Fecal samples Finegold
et al. (2002)Children with autism had nine species of Clostridium
not found in controls
Control children had three species of Clostridium not
found in autistic children Gastric and duodenal
Specimens
No non-spore-forming anaerobes and microaerophilic
bacteria from controls signiﬁcant numbers of
non-spore-forming anaerobes and microaerophilic
bacteria in children with autism
Pyrosequencing, fecal
microbiota
Autistic (n=33)
Non-affected siblings (n=7), HS
(n=8)
↑ Increased diversity and richness in the autistic
gastrointestinal microbiome
Finegold
et al. (2010)
↑ Bacteroidetes in the severely autistic group
↑ Firmicutes in the control group
↑ Desulfovibrio species and Bacteroides vulgatus
autistic children
IBS-D, diarrhea predominant IBS; IBS-C, constipation predominant IBS; IBS-A, alternating IBS; UC, ulcerative colitis; CD, Crohn’s disease; IC, infectious colitis; HS,
healthy subjects; DGGE, denaturing gradient gel electrophoresis; Q-PCR, quantitative PCR; FISH, ﬂuorescent in situ hybridization; T-RFLP, terminal restriction length
polymorphism.
probiotic therapies in the alleviation of key symptoms in IBS
(Abdominal pain/discomfort, bloating/distension, alterations in
defecatory function; Moayyedi et al., 2008; Brenner et al., 2009;
Whorwell, 2009).
Recent research supporting a role for the microbiota in main-
taining normal brain function offers the intriguing possibility
that the therapeutic targeting of the gut microbiome might be
a viable strategy in the treatment of CNS disorders (Forsythe
et al., 2010). Some validation for this approach can be seen in the
results of a recent study which demonstrated beneﬁcial psycholog-
ical effects in healthy human volunteers following administration
of a combination of L. helveticus R0052 and B. longum R0175
(Messaoudi et al., 2011). However this ﬁeld of research is still in
its infancy with few studies exploring the concept of microbial
targeting of the GIT under pathological conditions of the CNS.
Nevertheless, studies that have employed this strategy have gener-
ated encouraging results. B. infantis 35624 treatment, for example,
was shown to normalize immune responses, reverse behavioral
deﬁcits in the forced swim test, and restore basal noradrena-
line concentrations in the brainstem of adult rats subjected to
the early life stress of maternal separation, an animal model of
brain–gut axis dysfunction (Desbonnet et al., 2010; O’Mahony
et al., 2011). Of further interest is that a preclinical study using the
same probiotic found that CRD-induced visceral pain behaviors
were signiﬁcantly reduced in the viscerally hypersensitive Wistar-
Kyoto rat strain (McKernan et al., 2010). L. paracasei NCC2461
administration has also shown efﬁcacy in reducing visceral hyper-
sensitivity in a mouse preclinical model of IBS (Verdu et al.,
2006).
Few studies have made an attempt to unravel the mystery
surrounding the mechanism of action of probiotics. However a
number of theories exist, many of which relate to the previously
elucidated role of the microbiota in health. The possibility that
the administered probiotic might restore the distorted bacterial
ﬂora to one resembling that of healthy individuals is partially
supported by a study demonstrating exactly such a phenomenon
with a multispecies probiotic preparation previously shown to
be effective in the treatment of IBS (Kajander et al., 2005; Lyra
et al., 2010). Similarly alterations in the fecal metabolome follow-
ing administration of an alternative probiotic preparation were
linked to its previously demonstrated efﬁcacy (Hong et al., 2009,
2011). However experts in the ﬁeld consider such a mechanism,
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along with the assumption of competition with and exclusion
of pathogens, to be overly simplistic and undermined by an
incomplete knowledge of what constitutes a“normal”microbiome
(Quigley, 2009).
The notion that efﬁcacious probiotic strains might exert their
beneﬁcial effects through modulation of host immunity is gain-
ing traction, especially in the light of the expanding repertoire of
studies supporting a low grade inﬂammation in IBS (Clarke et al.,
2009b). Of the strains evaluated,B. Infantis 35624 has been shown
to normalize abnormal IL-10/IL-12 ratios in addition to showing
efﬁcacy in treatment of the disorder (O’Mahony et al., 2005). That
certain probiotics might work by enhancing barrier function and
motility has also been considered and is supported primarily by
data from Ussing chamber studies. B. breve C50 and its soluble
factors have been shown to alleviate chloride secretion in human
intestinal epithelial cells (Heuvelin et al., 2009). Bioactive peptide
factors secreted by probiotics have been shown to enhance epithe-
lial cell barrier function both in vitro and in vivo (Ewaschuk et al.,
2008). Pretreatmentwith a probioticmixture containingL. helveti-
cus and L. rhamnosus was shown to prevent bacterial translocation
and improve intestinal barrier function in rats following chronic
psychological stress (Zareie et al., 2006). Similarly, L. Plantarum
299V was shown to inhibit Escherichia coli-induced intestinal per-
meability (Mangell et al., 2002). The involvement of the vagus
nerve is also considered likely in the light of recent studies (Bravo
et al., 2011; Cryan and O’Mahony, 2011). In reality the mecha-
nism of action is likely to be multifactorial with particular strains
exerting their inﬂuence either though one or more of the modes
outlined above or via a yet unidentiﬁed means.
Despite the demonstrated efﬁcacy of microbiota manipulation
in clinical disorders of the GIT, the potential utility of the strat-
egy in the treatment of CNS disorders as gleaned from preclinical
data and an improved understanding of the mechanisms involved,
a number of caveats still exist surround this approach generally.
One such limitation is the mixed results that have been obtained
in organic disorders of the GIT such as IBD where controlled tri-
als in CD have generally been disappointing as against the more
favorable results in UC (Shanahan, 2010b). There is also a paucity
of data pertaining to the long term effects of microbiome manip-
ulation although it is encouraging to note that a trial with a mul-
tispecies probiotic preparation conducted over 5months showed
major beneﬁts for both distension and abdominal pain in con-
junction with a stabilization of the microbiota and was completed
without any adverse effects (Kajander et al., 2008). It is also impor-
tant to note the potential beneﬁts of a treatment option with an
enviable safety record and negligible toxicity proﬁle compared to
conventional pharmacological approaches (Kopp-Hoolihan,2001;
Parvez et al., 2006). Regulatory hurdles also need to be clearedwith
the current classiﬁcation of probiotics as food supplements limit-
ing sanctioned use to healthy populations and functional claims
over recommendations for application to the treatment of disease
states (Marteau, 2010). Even these functional claims are the sub-
ject of controversy with agencies like the European Food Safety
Authority (EFSA) in disagreement with advocates of probiotics
over what constitutes solid scientiﬁc evidence for a particular
health claim (Guarner et al., 2011). In reality we are probably quite
some way from where this will be a serious issue for the appli-
cation of microbiome manipulation to the treatment of speciﬁc
CNS disorders but it is already a major impediment facing those
who are currently seeking to use the approach for gastrointestinal
afﬂictions.
CONCLUSION AND FUTURE PERSPECTIVES
The microbiome has assumed its rightful position as a critical
component of the brain–gut axis and a key factor in both health
and disease, a fact reﬂected in current research efforts. Previ-
ously determined functions of the microbiota have been bolstered
with exciting new studies highlighting its potential involvement
in a range of disorders as well as its impact on behavior and
mood at the level of the CNS. Recent ﬁndings raise the possi-
bility that therapeutic targeting of the microbiome might be an
effective treatment strategy for speciﬁc disorders of the CNS. This
needs to be tempered by the realization that we are still some way
from being able to completely differentiate a normal microbiota
from that present in disease or recognizing how its individual
components and collective signature are critical for health. Fur-
thermore although recent mechanistic insights have provided a
solid platform for future studies, an advanced understanding of
the interactions that occur is still lacking and warrants further
research. Whether the approach of microbiome manipulation will
evolve into a therapy in its own right or become an adjuvant to
conventional therapy is also still unclear (Aragon et al., 2010).
While this will involve clariﬁcation on the speciﬁc assessment cri-
teria for successful health claims by agencies like FDA and EFSA,
it also remains to be seen whether probiotic manufacturers will
be willing to subject their products to assessment by the rigor-
ous clinical trials that would be necessary for speciﬁed use of their
products in the treatment of disease states. In this context, support-
ing gut health through microbiota supplementation with a view
toward positively inﬂuencing mental status represents a putative
preventative strategy worth following (Bischoff, 2010). In addi-
tion to consideration of the microbiome as a therapeutic target,
we also need to direct more efforts toward mining its metabo-
lites for putative drugs, a strategy that has already paid some
dividends (Shanahan, 2010a). It is unmistakable that brain–gut–
microbiome communication in health and disease will continue
to occupy the minds of researchers and that the multidisciplinary
approaches that have brought us thus far will be evident in meet-
ing the exciting challenges that lie ahead. The likelihood is that we
have only seen the tip of the iceberg in this rapidly expanding area
of research.
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